Profile - Nutritional Products, Diagnostics, Medical Devices and Established Pharmaceuticals
Business at a Glance
- Adult Nutrition
- Pediatric Nutrition
- Performance Nutrition
- Core Laboratory
- Point of Care
- Medical Optics
- Diabetes Care
- Animal Health
- Established brands (primarily branded generics) sold outside the United States
Abbott nutritional products support the growth, health and wellness of people of all ages. With a strong commitment to innovation, Abbott prides itself on meeting the changing nutritional needs of consumers and healthcare professionals.
Our leading pediatric portfolio includes the Similac brand of infant formulas, Gain growing-up milks for toddlers and the PediaSure brand of complete, balanced nutrition for children. Similac is one of the leading infant formulas in the United States and is growing rapidly in emerging markets.
Abbott is the global leader in adult nutrition. As conditions such as heart disease, muscle loss, diabetes and cancer become more prevalent, good nutrition will play a larger role in enhancing patient care. Our Ensure line of products provides balanced nutrition and helps to rebuild muscle and lean body mass to support recovery. Glucerna shakes and bars are formulated for people with diabetes to help manage blood glucose levels as part of a diabetes management plan.
Abbott also markets products for active adults seeking convenient nutrition, including ZonePerfect bars and EAS sports nutrition bars and drinks.
Growing populations and increasing personal incomes are driving demand for Abbott nutritional products in markets such as China, Southeast Asia and Latin America.
Core Laboratory Diagnostics
An estimated 60 percent of all decisions regarding a patient’s diagnosis and treatment, hospital admission and discharge are based on laboratory test results. Abbott’s portfolio of leading tests provides the link between a patient’s symptoms and a physician’s diagnosis. Our broad line of diagnostic instruments and tests is used worldwide in hospitals, large reference laboratories, small labs and clinics to diagnose and monitor a range of serious health concerns, including infectious diseases, cancer, diabetes and cardiac issues.
Healthcare professionals use our tests and diagnostic systems, Prism, Architect and Cell-Dyn, to protect the blood supply, monitor medication levels and assist in the diagnosis and monitoring of diseases and disorders. Abbott is transforming the practice of medical diagnostics through new tests and systems that may lower costs, improve productivity and enhance patient care.
Point of Care Diagnostics
i-STAT, our point-of-care hand-held diagnostic system provides healthcare professionals in nearly 1,000 emergency departments the information they need to accelerate patient treatment decisions. With a few drops of blood, the i-STAT system provides rapid results in cardiac diagnosis and routine diagnostic assessments. In 2011, Abbott introduced a new, wireless version of the i-STAT system, which allows caregivers to share critical test information electronically without leaving the patient’s bedside. Moving forward, Abbott plans to further extend our point-of-care testing presence through international expansion and the launch of new products.
Abbott is changing disease diagnosis through advances in molecular testing. Years of medical treatment have demonstrated that no medicine works for every patient. In companion diagnostics, Abbott is developing more sensitive molecular tests that can identify which patients are more likely to benefit most from a particular therapy.
By providing better tests and instruments to healthcare providers, patients will receive appropriate treatment faster and benefit from a more targeted approach. Abbott markets tests that are used to screen patients for appropriate use of therapies for breast and non-small cell lung cancers. We are working to develop tests to identify patients who are best suited for treatments of additional cancer types.
Abbott also is a leader in infectious disease diagnosis and has an established portfolio to aid in clinical research and microbial identification, including our PlexID system.
With a premier pipeline and a broad product portfolio, Abbott is dedicated to improving the treatment of coronary artery disease (CAD), which takes the lives of an estimated 17 million people worldwide each year. CAD occurs when arteries that supply blood to the heart become blocked. Drug-eluting stents (DES) are placed in diseased arteries to reestablish blood flow. In 2011, we launched Xience PRIME, our next-generation DES, and Xience nano, our small-vessel DES, in the United States.
In January 2011, we announced the European approval of Absorb, the world’s first drug-eluting bioresorbable vascular scaffold (BVS) for CAD. Absorb has the potential to change the way physicians treat CAD. It does what no metallic DES can do—dissolve over time after the vessel is treated, much like sutures are absorbed after securing a wound. Abbott also is studying BVS technology for the treatment of peripheral artery disease.
In addition to CAD, Abbott is advancing the treatment of peripheral vascular, structural heart and carotid artery diseases. Our MitraClip system, which is designed to repair a patient’s leaking mitral heart valve, is available in a number of international markets and is an investigational device under U.S. Food and Drug Administration (FDA) review. Abbott also markets carotid stents, embolic protection devices, balloons, guide wires and vessel closure devices.
Diabetes affects more than 340 million people worldwide. Blood glucose monitoring is an important step in effective diabetes management. Abbott markets blood glucose monitoring systems that are easy to use, require small blood samples and provide fast and accurate results.
In 2011 in Europe, Abbott introduced the FreeStyle InsuLinx Blood Glucose Monitoring System, a unique blood glucose monitor that includes a meal-time insulin calculator. This technology is the foundation for our new diabetes product pipeline, which is dedicated to further improving the testing experience for patients.
Vision care is a growing area of need among people of all ages. Abbott is the leader in refractive products, including LASIK, and a leader in the growing cataract surgery market. Abbott markets a state-of-the-art line of intraocular lenses (IOLs) to restore a patient’s vision following cataract surgery. Our broad selection of corneal products serves patients who wear contact lenses or need relief from dry, irritated eyes.
Over the next five years, Abbott plans to launch a number of new products in vision care and further expand into key markets such as India and China.
Abbott leverages its strengths in human health to advance veterinary medicine. We market blood glucose monitoring systems for cats and dogs, as well as products for wound care and nutrition. Our surgical product line addresses veterinary needs in anesthesia, fluid therapy and medical devices.
Abbott has a diverse portfolio of more than 500 established pharmaceutical products spanning dozens of therapeutic categories. Our branded generic pharmaceutical product portfolio is backed by quality, consistent efficacy and safety, and a reliable supply chain.
Abbott is expanding its presence in key developed and developing countries. Emerging markets, an important part of our growth strategy, are the world’s fastest-growing regions, driven by evolving demographics, rising incomes, modernization of healthcare systems and increased treatment of chronic diseases. Our growth strategies have enabled us to secure the number-one pharmaceutical position in India, one of the world’s fastest-growing pharmaceutical markets.
Over the next several years, we expect to further expand our established products presence through more than 1,000 launches, including expansions across multiple geographies.